U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H27NO2
Molecular Weight 337.4553
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMINEPTINE

SMILES

OC(=O)CCCCCCNC1C2=CC=CC=C2CCC3=C1C=CC=C3

InChI

InChIKey=ONNOFKFOZAJDHT-UHFFFAOYSA-N
InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25)

HIDE SMILES / InChI

Description

Amineptine is a selective inhibitor of dopamine reuptake. The drug was developed in France and was marketed for the treatment of depressive disorders under the name Survector among the others. Amineptine was withdrawn from the French market in 1999 because of abuse and drug dependence and because of its hepatic (cholestatic injuries) and cutaneous (acne) adverse effects.

CNS Activity

Approval Year

Unknown
127998
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Withdrawn
Survector

Approved Use

Survector 100mg tablet is used in the treatment of depression.

Launch Date

2.52460794E11
PubMed

PubMed

TitleDatePubMed
[Extensive multicentric study of 1354 cases of depressed subjects treated with amineptin].
1982
[Amineptin-induced hepatitis: differential diagnosis of biliary microlithiasis].
1982 Nov
[Hepatitis due to amineptin. 4 cases].
1982 Nov
[Amineptin dependence and iatrogenic acne. Review of the literature apropos of a case].
1991 Dec
Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme.
2001 Mar
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.
2002 Dec
Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice.
2003 Jul
Is it possible to be dependent to Tianeptine, an antidepressant? A case report.
2007 Apr 13
Prevalence of antidepressants and biosimilars in elite sport.
2009 Jun
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Research on antidepressants in India.
2010 Jan
Patents

Patents

US8158152
7

Sample Use Guides

In Vivo Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/21584062
Patients receive 200 mg of amineptine (survector) daily, in two divided doses at 8 A.M. and 12 noon for 6 weeks.
Route of Administration: Oral
In Vitro Use Guide
Rat neurones were treated with 300 nM-30uM of amineptine. Amineptine (1-30uM) decreased spontaneous firing and slightly hyperpolarized the membrane potential. At 300 nM-30uM amineptine increased the amplitude and duration of responses to exogenously applied dopamine.
Name Type Language
AMINEPTINE
INN   MI   WHO-DD  
INN  
Official Name English
7-((10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)AMINO)HEPTANOIC ACID
Systematic Name English
AMINEPTINE [MI]
Common Name English
AMINEPTIN
Common Name English
Amineptine [WHO-DD]
Common Name English
amineptine [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QN06AA19
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
WHO-ATC N06AA19
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
NCI_THESAURUS C265
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
Code System Code Type Description
EPA CompTox
DTXSID1048831
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
RXCUI
17698
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY RxNorm
INN
3998
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
WIKIPEDIA
AMINEPTINE
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
MESH
C011597
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
MERCK INDEX
M1673
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY Merck Index
CHEBI
32499
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
EVMPD
SUB05435MIG
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
NCI_THESAURUS
C74142
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
ECHA (EC/EINECS)
260-818-0
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
PUBCHEM
34870
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
FDA UNII
27T1I13L6G
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
DRUG CENTRAL
161
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
ChEMBL
CHEMBL418995
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
CAS
57574-09-1
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
DRUG BANK
DB04836
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
ACTIVE MOIETY
Structure of AMINEPTINE
SALT/SOLVATE (PARENT)
Structure of AMINEPTINE SODIUM
SALT/SOLVATE (PARENT)
Structure of AMINEPTINE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966